At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
OPC-64005 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Oct 27, 2017·Updated Oct 29, 2021
In Brief
A Phase 2 clinical trial evaluating OPC-64005, Atomoxetine, and 1 other intervention for Adult Attention Deficit Hyperactivity Disorder. Completed, enrolled 239 participants across 26 sites.
Detailed Summary
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionOct 2018
TodayJul 2026
First PostedOct 27, 2017
Enrollment StartNov 9, 2017
Primary CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.7 years ago
Interventions
OPC-64005drug
OPC-64005 film coated tablets
Atomoxetinedrug
Atomoxetine gelatin capsules
Placebodrug
OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules